文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

自主人工智能即时筛查儿童糖尿病视网膜病变的成本效益

Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该经济评价基于文献参数,比较自主AI即时筛查与眼保健专业人员标准筛查在儿童1型和2型糖尿病视网膜病变中的成本效益。结果显示自主AI筛查的真阳性比例更高,但基础情景下患者支付更高;当筛查依从性至少23%时,自主AI筛查成为优选策略。结论提示在推荐依从率下,自主AI即时筛查有效且节省成本。

要点

  • 自主AI筛查真阳性比例高于标准筛查(T1D 0.03 vs 0.006,T2D 0.04 vs 0.01)。
  • 基础情景20%依从性下,自主AI患者自付费用更高。
  • 依从性至少23%时,自主AI筛查成为优选策略。

核心结论

  • 在推荐依从率下,自主AI即时筛查对糖尿病儿童及其照护者有效且节省成本。

研究设计与样本

  • 经济评价,参数估计来自1994至2019年文献,评估时间为2019年3月至2020年1月。

主要发现

  • 标准眼保健专业人员筛查的预期真阳性比例:1型糖尿病0.006,2型糖尿病0.01。
  • 自主AI筛查的预期真阳性比例:1型糖尿病0.03,2型糖尿病0.04。
  • 基础情景20%依从性下,自主AI筛查的平均患者支付更高(1型糖尿病8.52美元,2型糖尿病10.85美元) vs 标准筛查(1型糖尿病7.91美元,2型糖尿病8.20美元)。
  • 当至少23%的患者依从糖尿病视网膜病变筛查时,自主AI筛查为优选策略。

关键数值与推荐

  • 自主AI筛查真阳性比例:1型糖尿病0.03,2型糖尿病0.04;标准筛查:1型糖尿病0.006,2型糖尿病0.01。
  • 基础情景20%依从性下患者平均支付:自主AI 1型糖尿病8.52美元、2型糖尿病10.85美元;标准筛查1型糖尿病7.91美元、2型糖尿病8.20美元。
  • 自主AI筛查成为优选策略的依从性阈值为至少23%。

临床怎么用

  • 在儿童糖尿病视网膜病变筛查中,可考虑自主AI即时筛查以提高真阳性检出。
  • 实施自主AI筛查需关注患者自付费用,尤其在低依从性情景下。
  • 确保筛查依从性至少达到23%以使自主AI筛查具有成本效益优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Screening for diabetic retinopathy is recommended for children with type 1 diabetes (T1D) and type 2 diabetes (T2D), yet screening rates remain low. Point-of-care diabetic retinopathy screening using autonomous artificial intelligence (AI) has become available, providing immediate results in the clinic setting, but the cost-effectiveness of this strategy compared with standard examination is unknown. OBJECTIVE: To assess the cost-effectiveness of detecting and treating diabetic retinopathy and its sequelae among children with T1D and T2D using AI diabetic retinopathy screening vs standard screening by an eye care professional (ECP). DESIGN, SETTING, AND PARTICIPANTS: In this economic evaluation, parameter estimates were obtained from the literature from 1994 to 2019 and assessed from March 2019 to January 2020. Parameters included out-of-pocket cost for autonomous AI screening, ophthalmology visits, and treating diabetic retinopathy; probability of undergoing standard retinal examination; relative odds of undergoing screening; and sensitivity, specificity, and diagnosability of the ECP screening examination and autonomous AI screening. MAIN OUTCOMES AND MEASURES: Costs or savings to the patient based on mean patient payment for diabetic retinopathy screening examination and cost-effectiveness based on costs or savings associated with the number of true-positive results identified by diabetic retinopathy screening. RESULTS: In this study, the expected true-positive proportions for standard ophthalmologic screening by an ECP were 0.006 for T1D and 0.01 for T2D, and the expected true-positive proportions for autonomous AI were 0.03 for T1D and 0.04 for T2D. The base case scenario of 20% adherence estimated that use of autonomous AI would result in a higher mean patient payment ($8.52 for T1D and $10.85 for T2D) than conventional ECP screening ($7.91 for T1D and $8.20 for T2D). However, autonomous AI screening was the preferred strategy when at least 23% of patients adhered to diabetic retinopathy screening. CONCLUSIONS AND RELEVANCE: These results suggest that point-of-care diabetic retinopathy screening using autonomous AI systems is effective and cost saving for children with diabetes and their caregivers at recommended adherence rates.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wolf RM, Channa R, Abramoff MD, et al. Cost-effectiveness of Autonomous Point-of-Care Diabetic Retinopathy Screening for Pediatric Patients With Diabetes. JAMA Ophthalmol. 2020. PMID: 32880616. doi:10.1001/jamaophthalmol.2020.3190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。